Cost-effectiveness of community-acquired pneumonia therapy

References

• Garibaldi RA. Epidemiology of community- acquired respiratory tract infections in adults: incidence, etiology and impact. Am.j Merl 78, S32—S37 (1985).
   Google Scholar
• Niederman MS, McCombs JI, Unger AN, Kumar A, Popovian R. The cost of treating community-acquired pneumonia. Clin. Ther 20, 820–837 (1998).
   Google Scholar
• •Detailed economic analysis of the costs associated with the treatment of community-acquired pneumonia, both in the out- and inpatient setting.
   Google Scholar
• Torres A, Serra-Batlles J, Ferrer A eta]. Severe community-acquired pneumonia. Epidemiology and prognostic factors. Am. Rev Respir. Dis. 144,312–318 (1991).
   Google Scholar
• Niederman MS, Bass JB, Campbell GD etal Guidelines for the initial management of adults with community-acquired pneumonia: diagnosis, assessment of severity and initial antimicrobial therapy. Am. Rev Respir. Dis. 148, 1418–1426 (1993).
   PubMed Web of Science ®Google Scholar
• Niederman MS, Mandell LA, Anzueto A etal Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy and prevention. A117. I Respir. Cat. Cam Merl 163,1730–1754 (2001).
   Google Scholar
• ••Extensively referenced, evidence-based guideline for the treatment of community-acquired pneumonia has profoundly influenced pneumonia care.
   Google Scholar
• Reeder CE. Overview of pharmacoeconomics and pharmaceutical outcomes evaluations. Am. J. Health Syst. Pharm. 52(19), S5—S8 (1995).
   Google Scholar
• Syrjam H, Broas M, Suramo I, Ojala A, Uhde S. High-resolution computed tomography for the diagnosis of community-acquired pneumonia. Gun. Infect. Dis. 27,358–363 (1998).
   Google Scholar
• Bartlett JG, Dowell SF, Mandell LA, File TM, Musher DM, Fine MJ. Practice guidelines for the management of community-acquired pneumonia in adults. Clin. Infect. Dis. 31,347–382 (2000).
   PubMed Web of Science ®Google Scholar
• •Well referenced, influential guideline.
   Google Scholar
• Meehan TP, Fine MJ, Krumholz HM etal Quality of care, process and outcomes in elderly patients with pneumonia. JA11/14 278,2080-2084 (1997).
   Google Scholar
• ••Demonstrates that the timing of initialantibiotics is an important determinant of patient outcomes.
   Google Scholar
• Skerret SJ. Diagnostic testing for community-acquired pneumonia. Gun. Chest Med 20,531–548 (1999).
   PubMedGoogle Scholar
• Waterer GW, Jennings SG, Wunderink RG. The impact of blood cultures on antibiotic therapy in pneumococcal pneumonia. Chest 116,1278–1281 (1999).
   Google Scholar
• Bryan CS. Blood cultures for community-acquired pneumonia. No place to skimp! Chest 116,1153–1155 (1999).
   PubMedGoogle Scholar
• Glerant JC, Hellmuth D, Schmit JL, Ducroix JP, Jounieaux V. Utility of blood cultures in community-acquired pneumonia requiring hospitalization: influence of antibiotic treatment before admission. Respir. Med 93,208–212 (1999).
   Google Scholar
• Fine MJ, Auble TE, Yealy DM eta]. A prediction rule to identify low-risk patients with community-acquired pneumonia. NewEngLj Med 336,243–250 (1997).
   Google Scholar
• ••Seminal article describing an evaluationtool which predicted the risk of mortality in patients admitted to the hospital with community-acquired pneumonia.
   Google Scholar
• Marrie, TJ, Lau CY, Wheeler SL, Wong CJ, Vandervoort MK, Feagan BG. A controlled trial of a critical pathway for treatment of community-acquired pneumonia. J411'14 238,749-755 (2000).
   Google Scholar
• ••Large controlled study demonstrating adecrease in the hospital admission rate when the pneumonia severity index was used to help guide the admission decision.
   Google Scholar
• Marras TK, Gutierrez C, Chan CK. Applying a prediction rule to identify low-risk patients with community-acquired pneumonia. Chest 118, 1339–1343 (2000).
   Google Scholar
• Angus DC, Marrie TJ, Obrosky S etal Severe community-acquired pneumonia. Use of intensive care services and evaluation of American and British thoracic society diagnostic criteria. Am J Respir Grit. Care Med 166,717–723 (2002).
   PubMed Web of Science ®Google Scholar
• Ewig S, Ruiz M, Mensa J etal Severe community-acquired pneumonia: assessment of severity criteria. Arn I Respir Grit. Care Med 158,1102–1108 (1998).
   PubMed Web of Science ®Google Scholar
• British Thoracic Society. Guidelines for the management of community-acquired pneumonia in adults admitted to hospital. Br. J. Hasp. Med. 49,346–350 (1993).
   PubMed Web of Science ®Google Scholar
• Gleason PP, Meehan TP, Fine JM, Galusha DH, Fine MJ. Associations between initial antimicrobial therapy and medical outcomes for hospitalized elderly patients with pneumonia. Arch. Intern. Med 159 (21), 2562–2572 (1999).
   Google Scholar
• Houck PM, MacLehose RF, Niederman MS, Lowery JK. Empiric antibiotic therapy and mortality among medicare pneumonia in-patients in 10 western states. Chest 119, 1420–1426 (2001).
   PubMed Web of Science ®Google Scholar
• Najib MM, Goss TF, Stein GE. Cost- effectiveness of sparfloxacin compared with other oral antimicrobials in outpatient treatment of community-acquired pneumonia. Pharmacotherapy 20 (4), 461–469 (2000).
   PubMedGoogle Scholar
• Dresser LD, Niederman MS, Paladino JA. Cost-effectiveness of gatifloxacin vs. ceftriaxone with a macrolide for the treatment of community-acquired pneumonia. Chest 119,1439–1448 (2001).
   Google Scholar
• Cassiere HA, Fein AM. Duration and route of antibiotic therapy in community-acquired pneumonia: switch and step-down therapy. Sem. In Resp. Infect. 13(1), 36–42 (1998).
   Google Scholar
• Ramirez JA, Srinath L, Ahkee S, Huang A, Raff MJ. Early switch from intravenous to oral cephalosporins in the treatment of hospitalized patients with community-acquired pneumonia. Arch. Intern. Med 155,1273–1276 (1995).
   Google Scholar
• Ramirez JA, Vargas S, Ritter GW, Brier ME, Wright A, Smith S. Early switch from intravenous to oral antibiotics and early hospital discharge. A prospective observational study of 200 consecutive patients with community-acquired pneumonia. Awl?. Intern. Med 159, 2449–2454 (1999).
   Google Scholar
• Rhew DC, Tu GS, Ofman J, Henning JM, Richards MS, Weingarten SR. Early switch and early discharge strategies in patients with community-acquired pneumonia; a meta-analysis. Acch. Intern. Med 161, 722–727 (2001).
   PubMedGoogle Scholar
• Milkovich G. Intravenous-to-oral transition therapy in community-acquired pneumonia: the INOVA health system experience. Phatmacotherapy21(7), 83–88 (2001).
   Google Scholar
• Halm EA, Switzer GE, Mittman BS, Walsh MB, Chang CCH, Fine MJ. What factors influence physician's decision to switch from intravenous to oral antibiotics for community-acquired pneumonia? J. Gen. Intern. Med 16,599–605 (2001).
   PubMedGoogle Scholar
• Paladin° JA, Gudgel LD, Forrest A, Niederman MS. Cost-effectiveness of intravenous-to-oral switch therapy. Azithromycin vs. cefuroxime with or without erythromycin for the treatment of community-acquired pneumonia. Chest 122,1271–1279 (2002).
   Google Scholar
• •Early switch from parenteral to enteral antibiotic found to be associated with decreased hospital length of stay and cost savings.
   Google Scholar
• Rhew DC, Hackner D, Henderson L, Ellrodt AG, Weingarten SR. The clinical benefit of in-hospital observation in low-risk pneumonia patients after conversion from parenteral to oral antimicrobial therapy. Chest 113(1), 142–146 (1998).
   PubMedGoogle Scholar
• Metersky ML. Community-acquired pneumonia: process of care studies. CUI7: Opin. Infect. Dis. 15,169-174 (2002).
   Google Scholar
• Nathwani D, Rubinstein E, Barlow G, Davey P. Do guidelines for community-acquired pneumonia improve the cost-effectiveness of hospital care? Clin. Infect. Dis. 32,728–741 (2001).
   Google Scholar
• Gora-Harper ML, Rapp RP, Finney JR Development of a best-practice model at a university hospital to increase efficiency in the management of patients with community-acquired pneumonia. Am. J Health-Syst. Pharm. 57\(Suppl. 3), S6—S9 (2000).
   Google Scholar
• Moran GJ. New directions in anti-infective therapy for community-acquired pneumonia in the emergency department. Phatmacotherapy21(7), S95—S99 (2001).
   Google Scholar
• Dobbin CJ, Duggan CJ, Barnes DJ. The efficacy of an antibiotic protocol for community-acquired pneumonia. Med J Aus. 174,333–337 (2001).
   Google Scholar
• Finch RG, Low DE. A critical assessment of published guidelines and other decision-support systems for the antibiotic treatment of community-acquired respiratory tract infections. Gun. Mcm Infect. 8\(Suppl. 2), 69–91 (2002).
   Google Scholar
• Metersky ML, Tate JP, Fine MJ, Petrillo MK, Meehan TR Temporal trends in outcomes of older patients with pneumonia. Arch. Intern. Med 160(22), 3385–3391 (2000).
   Google Scholar
• Mullooly JP, Bennett MJ, Hornbrook MC et al. Influenza vaccination programs for elderly persons: cost-effectiveness in a health maintenance organization. Ann. Intern. Med. 121, 947–952 (1994).
   PubMed Web of Science ®Google Scholar
• Nichol KL, Margolis KL, Wuorenma J, Von Sternberg T The efficacy and cost-effectiveness of vaccination against influenza among elderly persons living in the community. N Engl. J. Med. 331, 778–784 (1994).
   PubMed Web of Science ®Google Scholar
• Jackson LA, Neuzil KM, Yu 0 etal Effectiveness of pneumococcal vaccine in older adults. N Engl. J. Med. 348, 1747–1755 (2003).
   Google Scholar
• Sisk JE, Moskowitz AJ, Whang W etal Cost-effectiveness of vaccination against pneumococcal bacteremia among elderly people. JAMA 278,1333–1339 (1997).
   PubMed Web of Science ®Google Scholar
• Gable CB, Holzer SS, Engelhart L et aL Pneumococcal vaccine: efficacy and associated cost savings. JAIVIA 264, 2910–2915 (1990).
   PubMed Web of Science ®Google Scholar
• Whitney CG, Farley MM, Hadler J eta]. Decline in invasive pneumococcal disease after the introduction of protein-polysaccaride conjugate vaccine. N Eng. Med. 348(18), 1737–1746 (2003).
   Google Scholar